Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2016 Jun 14:10:176.
doi: 10.1186/s13256-016-0963-y.

Crizotinib in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma in the setting of renal insufficiency: a case report

Shalin Kothari  1 , Najam Ud-Din  2 , Michele Lisi  3 , Thomas Coyle  2
Affiliations
Case Reports

Crizotinib in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma in the setting of renal insufficiency: a case report

Shalin Kothari et al. J Med Case Rep. .

Abstract

Background: In vitro studies confirmed cytoreductive anti-tumor activity of crizotinib in experimental models of anaplastic large cell lymphoma in 2007. One case series and a few case reports describe the use of crizotinib in relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Even though data are limited regarding the dose of crizotinib in renal insufficiency, our case was successfully treated with a lower dose of crizotinib.

Case presentation: We report the case of a 48-year-old white man who had progressive disease after three prior cycles of cyclophosphamide, doxorubicin, vincristine and prednisone and three cycles of ifosfamide, carboplatin, and etoposide, and was not a candidate for high-dose chemotherapy and transplant due to poor performance status and renal insufficiency; he had a complete and durable response to single agent crizotinib. Crizotinib was given at a reduced dose (250 mg once daily) due to his renal insufficiency. He has been in complete remission for more than 2 years.

Conclusions: Our experience confirms the activity of crizotinib in this disease; it suggests that long-term treatment with crizotinib is a reasonable option in patients who are not candidates for more aggressive therapy and indicates that crizotinib can be used successfully at reduced doses in patients with pre-existing renal insufficiency. The role and timing of crizotinib in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma is unclear, but the current literature that we review here provides promising results that may lead to studies of crizotinib earlier in the course of disease.

Keywords: ALK; Anaplastic large cell lymphoma; Crizotinib; Renal insufficiency.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
a 18F-fluorodeoxyglucose positron emission tomography/computed tomography on Day 0 shows significant retroperitoneal lymphadenopathy. b 18F-fluorodeoxyglucose positron emission tomography/computed tomography on Day 76 shows complete resolution of the retroperitoneal lymphadenopathy
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Stein H, Foss HD, Durkop H, Marafioti T, Delsol G, Pulford K, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96(12):3681–95. - PubMed
    1. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1994;263(5151):1281–4. doi: 10.1126/science.8122112. - DOI - PubMed
    1. Ferreri AJ, Govi S, Pileri SA, Savage KJ. Anaplastic large cell lymphoma. ALK-positive. Crit Rev Oncol Hematol. 2012;83(2):293–302. doi: 10.1016/j.critrevonc.2012.02.005. - DOI - PubMed
    1. Lowe EJ, Lim MS. Potential therapies for anaplastic lymphoma kinase-driven tumors in children: progress to date. Paediatr Drugs. 2013;15(3):163–9. doi: 10.1007/s40272-013-0027-3. - DOI - PMC - PubMed
    1. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111(12):5496–504. doi: 10.1182/blood-2008-01-134270. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources